Literature DB >> 1708057

Opioids potentiate contractile response of rabbit myocardium to the beta adrenergic agonist isoproterenol.

L A Kindman1, R E Kates, R Ginsburg.   

Abstract

Opioid agonists and antagonists have both been reported to augment myocardial contractile force in vitro. We reported that the strong opioid agonists morphine and levorphanol, the weak agonist dextrorphan (an optical isomer of levorphanol), and the opioid antagonist naloxone all potentiate the stimulatory effects of the beta-adrenergic agonist isoproterenol on isometric tension generated by isolated rabbit right ventricular myocardium. The EC50 of isoproterenol was found to be shifted leftward 2.7-, 5.4-, 5.3-, and 3.4-fold respectively (p less than 0.05 when compared with controls), when the opioids were added at a final concentration of 1 x 10(5) M. Lower concentrations of opioid or antagonist did not potentiate the effects of isoproterenol. The rank order potency for potentiation thus differs markedly from that of opioid analgesia. The observed potentiation is therefore not agonist specific and not stereospecific. Furthermore, the drugs alone at a range of concentration from 10(-8) to 10(-5) M had no effect on isometric tension generated. We conclude that opioid agonists and antagonists potentiate the response of ventricular myocardium to the effects of beta-adrenergic stimulation by a novel mechanism unrelated to the binding of these drugs to opioid receptors. The paradoxical augmentation of myocardial contractility by either class of agent under a variety of clinical and experimental conditions is thus explained by these findings. Either agent may interact with myocardial tissue to cause increased sensitivity to stimulation by circulating catecholamines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708057     DOI: 10.1097/00005344-199101000-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist.

Authors:  G H Rimoy; D M Wright; N K Bhaskar; P C Rubin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  A common molecular motif characterizes extracellular allosteric enhancers of GPCR aminergic receptors and suggests enhancer mechanism of action.

Authors:  Robert Root-Bernstein; Patrick F Dillon
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to "Biased Opioids"?

Authors:  Robert Root-Bernstein; Miah Turke; Udaya K Tiruttani Subhramanyam; Beth Churchill; Joerg Labahn
Journal:  Int J Mol Sci       Date:  2018-01-17       Impact factor: 5.923

4.  Glutathione and Glutathione-Like Sequences of Opioid and Aminergic Receptors Bind Ascorbic Acid, Adrenergic and Opioid Drugs Mediating Antioxidant Function: Relevance for Anesthesia and Abuse.

Authors:  Robert Root-Bernstein; Beth Churchill; Miah Turke
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.